UNSPSC 51183304: Vildagliptin

This classification denotes a protease inhibitor and anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I6B4B2U96P. European Medicines Agency schedules Vildagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25199. Vildagliptin generally arises in the molecular formula C17H25N3O2.

The term VILDAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations, for tariff and trade purposes, schedule vildagliptin under HS 29339990 and SITC 51577. As of Q4 2014, VILDAGLIPTIN remains US FDA's Preferred Term for this commodity. Vildagliptin bears US NLM identifiers UMLS ID C1570906 and NCI Concept Code C66653. SMILES: OC12CC3(NCC(=O)N4C(CCC4)C#N)CC(C1)CC(C3)C2.

UNSPSC 51183304 Vildagliptin is a Commodity code representing a specific pharmaceutical active ingredient supplied through state and local cooperative purchasing agreements. State and local governments procure vildagliptin and related generic pharmaceuticals primarily via multistate cooperative purchasing alliances that aggregate demand across participating state agencies, counties, municipalities, and other public health entities, leveraging volume discounts and standardized supply chains through authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) exemplifies this model, establishing master agreements that participating jurisdictions draw from to stock their health facilities and programs. Issuing bodies under this code include state departments of health and administration, state purchasing offices administering cooperative vehicles, and public health agencies in participating states. The work involves manufacturer pricing submissions, product availability certification, supply chain compliance documentation, and ongoing fulfillment through three-tier distribution channels (manufacturer to wholesaler to end user).

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products spanning Minnesota, Oregon, and other participating states, with proposals due March 26, 2026. The solicitation requires manufacturers to submit detailed pricing, National Drug Codes, product specifications, and compliance certifications (cGMP and DSCSA); maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson); and accept flexible pricing formats (flat price, net price, or WAC-minus). Evaluations weight price competitiveness at 75 percent, with fixed pricing, administrative compliance, EDI capability, and fee acceptance comprising the remainder. The awarded contract term runs two years for new vendors effective July 1, 2026, with optional extensions, while incumbents' amendments extend through June 30, 2028. MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs, and vendors must maintain comprehensive insurance including $5,000,000 general liability and $2,000,000 network security liability, with performance penalties ranging from $200 to $1,500 per violation.